Universe Pharmaceuticals Inc. (UPC) Earnings History
Net Loss8 years of earnings data (2018–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Universe Pharmaceuticals Inc. (UPC) Earnings Overview
As of June 22, 2026, Universe Pharmaceuticals Inc. (UPC) reported trailing twelve-month net income of -$12M, reflecting +26.5% year-over-year growth. The company earned $-22.01 per diluted share over the past four quarters, with a net profit margin of -20.6%.
Looking at the long-term picture, UPC's historical earnings data spans multiple years. The company achieved its highest annual net income of $11M in fiscal 2021.
Universe Pharmaceuticals Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including HCWB (-$2M net income, -14677.1% margin), XTLB (-$1M net income, -227.7% margin), NUVB (-$146M net income, -325.3% margin), UPC has outperformed on profitability metrics. Compare UPC vs HCWB →
UPC Earnings vs Peers
Earnings metrics vs comparable public companies
UPC Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$4M | +57.9% | -$3M | $-1055.75 | -20.6% | -16.3% |
| 2024 | -$9M | -41.6% | -$8M | $-1436.12 | -37.9% | -34.8% |
| 2023 | -$6M | +29.5% | -$4M | $-1040.53 | -19.1% | -10.9% |
| 2022 | -$9M | -177.2% | -$7M | $-1475.02 | -21.8% | -17.5% |
| 2021 | $11M | +49.8% | $14M | $2147.18 | 23.6% | 28.3% |
| 2020 | $8M | +0.1% | $10M | $1295.70 | 24.6% | 33.4% |
| 2019 | $8M | -0.7% | $10M | $1294.54 | 22.7% | 29.4% |
| 2018 | $8M | - | $10M | $1303.36 | 26.7% | 33.9% |
Download Data
Export UPC earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
UPC — Frequently Asked Questions
Quick answers to the most common questions about buying UPC stock.
What is UPC earnings per share (EPS)?
UPC trailing twelve-month (TTM) diluted EPS is $-22.01, reflecting +26.5% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2018 to 2025 is available in the table on this page.
What is Universe Pharmaceuticals Inc.'s net income?
Universe Pharmaceuticals Inc. (UPC) trailing twelve-month net income is $-12M as of 2025. Earnings grew +26.5% year-over-year.
Is UPC profitable?
UPC is not currently profitable on a TTM basis, reporting a net loss of $-12M. Net margin is -20.6%. Investors should monitor for a return to profitability.
What is UPC's earnings growth rate?
UPC compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2018 to 2025.
What are UPC's profit margins?
Universe Pharmaceuticals Inc. net profit margin is -20.6%, operating margin is -16.3%, and gross margin is +35.3%. Below-average margins reflect competitive or cost pressures. Return on Equity is -7.2%.
Is UPC growing earnings?
Yes, UPC earnings are accelerating — EPS growth of +26.5% exceeds the 5-year CAGR of N/A. TTM net income reached $-12M. Earnings momentum is strengthening.
What was UPC's best earnings year?
Universe Pharmaceuticals Inc.'s highest annual net income on record is $11M, achieved in fiscal year 2021. Earnings history on this page spans 2018 to 2025 and includes all annual and quarterly figures.
What were UPC's earnings last quarter?
UPC's most recent reported quarter was Q4 2025. Net income was $-387300.00 with diluted EPS of $-0.69. For a full breakdown of all quarters, see the quarterly earnings table on this page.